TY - JOUR
T1 - Prostate Cancer, Use of Androgen Deprivation Therapy, and Cognitive Impairment
T2 - A Population-based Study
AU - Alonso Quiñones, Hector J.
AU - Stish, Bradley J.
AU - Hagen, Clinton
AU - Petersen, Ronald C.
AU - Mielke, Michelle M.
N1 - Funding Information:
Supported by the National Institutes of Health National Institute on Aging grants U01 AG006786 and RF1 AG55151, the GHR Foundation, CTSA Grant Number UL1 TR002377 from the National Center for Advancing Translational Sciences (NCATS), a component of the National Institutes of Health (NIH), and was made possible by the Rochester Epidemiology Project (R01 AG034676).
Publisher Copyright:
© 2020 Lippincott Williams and Wilkins. All rights reserved.
PY - 2020/4/1
Y1 - 2020/4/1
N2 - Introduction:The association of prostate cancer and androgen deprivation therapy (ADT) use with the odds of developing mild cognitive impairment (MCI) was determined in men from the population-based Mayo Clinic Study of Aging (MCSA).Methods:The study included 2513 men (mean age of 73.1 y) enrolled in the MCSA. A history of prostate cancer, ADT use, and length of ADT exposure before their first MCSA visit was abstracted using the Rochester Epidemiology Project medical records-linkage system. MCI was diagnosed at the baseline visit. Logistic regression was used to determine whether prostate cancer and ADT use was associated with odds of MCI.Results:Of the 2513 participants, 349 (13.9%) had a history of prostate cancer; among whom 99 (28.3%) were treated with ADT before MCSA enrollment. There were 382 (15.2%) with a diagnosis of MCI. In the univariate logistic regression models, prostate cancer (odds ratio, 1.50; 95% confidence interval, 1.12-2.00), and ADT exposure (odds ratio, 1.57; 95% confidence interval, 0.96-2.58) were associated with higher odds of MCI. These associations were greatly attenuated and not significant in multivariable models.Conclusions:Neither a diagnosis of prostate cancer nor ADT use was associated with odds of MCI in this cross-sectional population-based study.
AB - Introduction:The association of prostate cancer and androgen deprivation therapy (ADT) use with the odds of developing mild cognitive impairment (MCI) was determined in men from the population-based Mayo Clinic Study of Aging (MCSA).Methods:The study included 2513 men (mean age of 73.1 y) enrolled in the MCSA. A history of prostate cancer, ADT use, and length of ADT exposure before their first MCSA visit was abstracted using the Rochester Epidemiology Project medical records-linkage system. MCI was diagnosed at the baseline visit. Logistic regression was used to determine whether prostate cancer and ADT use was associated with odds of MCI.Results:Of the 2513 participants, 349 (13.9%) had a history of prostate cancer; among whom 99 (28.3%) were treated with ADT before MCSA enrollment. There were 382 (15.2%) with a diagnosis of MCI. In the univariate logistic regression models, prostate cancer (odds ratio, 1.50; 95% confidence interval, 1.12-2.00), and ADT exposure (odds ratio, 1.57; 95% confidence interval, 0.96-2.58) were associated with higher odds of MCI. These associations were greatly attenuated and not significant in multivariable models.Conclusions:Neither a diagnosis of prostate cancer nor ADT use was associated with odds of MCI in this cross-sectional population-based study.
KW - androgen deprivation therapy
KW - case-control study
KW - dementia
KW - prostate cancer
UR - http://www.scopus.com/inward/record.url?scp=85077016213&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85077016213&partnerID=8YFLogxK
U2 - 10.1097/WAD.0000000000000366
DO - 10.1097/WAD.0000000000000366
M3 - Article
C2 - 31821185
AN - SCOPUS:85077016213
SN - 0893-0341
VL - 34
SP - 118
EP - 121
JO - Alzheimer disease and associated disorders
JF - Alzheimer disease and associated disorders
IS - 2
ER -